ValuEngine downgraded shares of Homology Medicines (NASDAQ:FIXX) from a buy rating to a hold rating in a report released on Friday morning.
A number of other equities research analysts have also recently weighed in on the company. B. Riley started coverage on Homology Medicines in a research note on Friday, September 7th. They issued a neutral rating and a $18.50 price objective for the company. Zacks Investment Research raised Homology Medicines from a hold rating to a buy rating and set a $19.00 price objective for the company in a research note on Thursday, August 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $25.90.
Shares of NASDAQ FIXX traded up $0.47 during trading on Friday, reaching $24.98. The stock had a trading volume of 134,952 shares, compared to its average volume of 140,074. Homology Medicines has a fifty-two week low of $15.07 and a fifty-two week high of $25.93.
Homology Medicines (NASDAQ:FIXX) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.03). The firm had revenue of $0.95 million during the quarter. As a group, research analysts anticipate that Homology Medicines will post -1.49 EPS for the current year.
In related news, major shareholder Ventures Iv L.P. 5Am sold 525,900 shares of Homology Medicines stock in a transaction on Friday, November 16th. The stock was sold at an average price of $20.20, for a total value of $10,623,180.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in Homology Medicines by 12.9% in the second quarter. FMR LLC now owns 3,359,715 shares of the company’s stock valued at $67,192,000 after purchasing an additional 384,818 shares during the period. JPMorgan Chase & Co. boosted its holdings in Homology Medicines by 29.7% in the third quarter. JPMorgan Chase & Co. now owns 2,251,444 shares of the company’s stock valued at $51,468,000 after purchasing an additional 516,156 shares during the period. Vivo Capital LLC boosted its holdings in Homology Medicines by 21.6% in the second quarter. Vivo Capital LLC now owns 1,409,742 shares of the company’s stock valued at $28,759,000 after purchasing an additional 250,000 shares during the period. BlackRock Inc. boosted its holdings in Homology Medicines by 17.4% in the third quarter. BlackRock Inc. now owns 623,350 shares of the company’s stock valued at $14,249,000 after purchasing an additional 92,373 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Homology Medicines by 0.7% in the third quarter. Vanguard Group Inc. now owns 473,945 shares of the company’s stock valued at $10,834,000 after purchasing an additional 3,504 shares during the period. Hedge funds and other institutional investors own 53.41% of the company’s stock.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Read More: What is the NASDAQ?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.